aidsmap news story
Two large studies have found that switching to an integrase inhibitor carries a moderately increased risk of developing type 2 diabetes for some groups of people with HIV.
In one study, which combined data from 27 cohorts of people receiving HIV care in North America, switching from a protease inhibitor to an integrase inhibitor increased the risk of developing type 2 diabetes within two years. Switching from a non-nucleoside reverse transcriptase inhibitor to an integrase inhibitor did not raise the risk of developing diabetes.
In a second study, of participants in the REPRIEVE trial of statin treatment for people with HIV at low-to-moderate risk of major cardiovascular events, switching to an integrase inhibitor raised the risk of developing type 2 diabetes within five years. The switch to an integrase inhibitor also raised the risk of developing obesity or high blood pressure, but was not associated with a raised risk of major cardiovascular events.
Read the full news story here.
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.